Please ensure Javascript is enabled for purposes of website accessibility

Why Surface Oncology Stock Is Soaring Today

By Keith Speights - Mar 31, 2021 at 11:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company received an orphan drug designation from the FDA for one of its lead pipeline candidates.

What happened

Shares of Surface Oncology (SURF 10.64%) had soared by 11.3% as of 10:44 a.m. EDT on Wednesday. The big gain came after the company announced late on Tuesday that the Food and Drug Administration had granted an orphan drug designation to its candidate drug SRF617 as a potential treatment for pancreatic cancer.

So what

Good news for pipeline candidates usually lights a spark beneath biotech stocks, especially those like Surface that only have early-stage candidates. So exactly how good is this latest news?

Mean wearing coat and tie holding yellow blocks in his hand spelling FDA

Image source: Getty Images.

The FDA grants orphan drug status only to treatments that target rare diseases and conditions for which it would normally be unprofitable to develop treatments. Companies that receive the designation for their candidates receive partial tax credits for their clinical study expenses. They don't have to pay the FDA's user fees for those drugs. And most importantly, such drugs can be eligible for seven years of marketing exclusivity in the U.S. if they are approved. This last benefit of the orphan drug designation can translate to a lot of extra money for drugmakers.

Surface Oncology is currently evaluating SRF617 in phase 1/1b studies targeting several types of solid tumors. These studies include a combination of the experimental drug with chemotherapy gemcitabine and Bristol Myers Squibb's Abraxane in treating pancreatic cancer.

Now what

The biotech plans to present preclinical data for SRF617 and for another pipeline candidate, SRF388, at the American Association for Cancer Research Virtual Annual Meeting in April. Surface Oncology also hopes to provide more detailed data for both experimental drugs at the American Society of Clinical Oncology Virtual Annual Meeting in June. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Surface Oncology, Inc. Stock Quote
Surface Oncology, Inc.
SURF
$2.08 (10.64%) $0.20
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$78.22 (1.70%) $1.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.